Ratio Therapeutics is a biotechnology company focused on developing antibiotics to combat antimicrobial resistance. The company leverages advanced computational approaches and machine learning algorithms to accelerate the discovery and development of new treatments against drug-resistant bacteria.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.

Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets.  Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Schusterman Family Investments

Duquesne Capital Management

The Pags Group

Bristol-Myers Squibb

Cornell University

#ICYMI— The recent announcement of our $50M Series B funding round was included in Crunchbase's roundup of the 10 biggest funding rounds of the week. The funding will help us continue to develop our cutting-edge #radiopharmaceuticals for diagnostics and cancer treatment.

https://lnkd.in/e8n3CrFN 

#radiopharma #oncology #funding #innovation

See Ratio featured in this article from Hannah Green of Boston Business Journal, where she interviewed Drs. Jack Hoppin, CEO, and John Babich, CSO, to learn more about how Ratio will use its $50M Series B financing to advance the applications of Ratio’s proprietary #radiopharmaceutical platforms, Trillium and Macropa and support clinical development of its fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic. 

Read here: https://lnkd.in/gBgFSWfZ

#innovation #seriesB #radiopharma

Thank you Kyle LaHucik for interviewing Drs. Jack Hoppin, CEO, and John Babich, CSO, for this Endpoints News article about Ratio’s Series B financing. Ratio raised $50M which will support the development of its #radiopharmaceuticals for treating #cancer, with its first therapeutic candidate targeting fibroblast activation protein-alpha (FAP) to enter the clinic this year.

Read here: https://lnkd.in/eRiUDY78

 #innovation #seriesB #radiopharma

This #WorldCancerDay, let's celebrate the strength and resilience of #cancer survivors and work to reimagine a world where access to life-saving cancer treatments is equitable for all. #CloseTheCareGap

At Ratio, we are committed to developing innovative #radiopharmaceutical therapies that target cancer cells with precision, while minimizing harm to healthy tissue.

Learn more: https://lnkd.in/drnuZeE

Interested in the outlook for the #radiopharmaceuticals space? BioSpace recently published this article predicting rapid growth of the market over the next decade.

Read here: https://lnkd.in/g4RXgJtc 

#biopharma #marketgrowth #cancertreatment

Today, Ratio is pleased to announce the close of a Series B financing bringing the total raised to date to over $90M. Ratio will use the proceeds to advance the development of targeted radiotherapeutics for cancer treatment, including the company’s proprietary technology platforms, Trillium™ and Macropa™ and to drive the clinical development of the company’s fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic.
 
Learn more: https://lnkd.in/emgjYm4M

#radiotherapeutics #biotech #nuclearmedicine #Funding

What's the next big thing in #radiopharmaceuticals?  Get a glimpse into the future with this article in STAT, including our Co-founder and CEO, Jack Hoppin, Ph.D.  

Read the article here: https://lnkd.in/eNG7x_83

#innovation #nuclearmedicine #biotech

#MeetTheTeam – Shawn Hillier, Ph.D., Ratio’s COO, brings a wealth of experience to Ratio, having worked in the industry for 18 years.

Shawn values the diverse backgrounds of Ratio’s team and our passion and commitment to improving the lives of cancer patients.

“Regardless if you're in the lab or in a G&A support function, the focus is on the patient, and the urgency to bring new radiopharmaceuticals to the patients we serve is real. Collaboration is key to an organization’s success and our team works well together with a focus on our mission.”

#innovation #radiopharmaceuticals #biotech

At Ratio Therapeutics, we're dedicated to developing innovative #radiopharmaceutical therapies that target #cancer cells with precision, while minimizing harm to healthy tissue. 

Learn more about our work: https://www.ratiotx.com

#ICYMI – Allison DeAngelis of STAT featured our Cofounders, CEO Jack Hoppin, Ph.D., and CSO John Babich, Ph.D., in this great article giving an overview of the #radiopharmaceutical industry. 

Read here: https://lnkd.in/eNG7x_83

COM:RATIOTX

Ratio Therapeutics